DeepMed Research

Pamiparib

Generic Name: Pamiparib

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₅FN_₄O

CAS Number: 1446261-44-4

Unique Ingredient Identifier: 8375F9S90C

Background: Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).

Indication: 用于既往经过二线及以上化疗的伴有胚系BRCA(gBRCA)突变的复发性晚期卵巢癌、输卵管癌或原发性腹膜癌患者的治疗。

Clinical Trials

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Peking University Shenzhen Hospital

Target Recruit Count: 200

Registration Number: NCT06692491

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Phase 2

Recruiting

Conditions: Oligometastatic Prostate Cancer
Locally Advanced Prostate Cancer

Interventions: Drug: Rezvilutamide
Drug: Goserelin Microspheres for Injection
Drug: Docetaxel
Drug: Pamiparib
Drug: Cisplatin
Drug: Tislelizumab

First Posted Date: 2024-04-26

Last Posted Date: 2024-04-26

Lead Sponsor: The First Affiliated Hospital of Xiamen University

Target Recruit Count: 40

Registration Number: NCT06387056

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Pamiparib
Drug: Surufatinib

First Posted Date: 2022-12-15

Last Posted Date: 2024-11-27

Lead Sponsor: Bai-Rong Xia

Target Recruit Count: 37

Registration Number: NCT05652283

Locations: 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Phase 1

Recruiting

Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Carcinoma
Head and Neck Cancer Stage IV
Head and Neck Cancers - Throat

Interventions: Radiation: Chemoradiation
Drug: Pamiparib
Drug: Hydroxyurea
Drug: Fluorouracil (5FU)
Drug: Tislelizumab

First Posted Date: 2022-09-02

Last Posted Date: 2024-11-22

Lead Sponsor: University of Chicago

Target Recruit Count: 30

Registration Number: NCT05526924

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Ovarian Carcinoma
Fallopian Tube Carcinosarcoma
Platinum-resistant Ovarian Cancer

Interventions: Drug: Pamiparib
Drug: Surufatinib

First Posted Date: 2022-08-10

Last Posted Date: 2023-04-11

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 38

Registration Number: NCT05494580

Locations: 🇨🇳
Sun Yat-sen University Cancer Cetntre, Guangzhou, China

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Phase 2

Active, not recruiting

Conditions: Epithelial Ovarian Cancer

Interventions: Drug: Pamiparib

First Posted Date: 2022-08-05

Last Posted Date: 2024-01-26

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 15

Registration Number: NCT05489926

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Phase 2

Recruiting

Conditions: Limited Stage Small Cell Lung Cancer

Interventions: Drug: Pamiparib

First Posted Date: 2022-08-02

Last Posted Date: 2022-08-02

Lead Sponsor: Fudan University

Target Recruit Count: 44

Registration Number: NCT05483543

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

Phase 2

Recruiting

Conditions: Neoadjuvant Therapy

Interventions: Drug: pamiparib
Drug: abiraterone
Drug: prednisone

First Posted Date: 2022-05-17

Last Posted Date: 2023-01-05

Lead Sponsor: Hongqian Guo

Target Recruit Count: 30

Registration Number: NCT05376722

Locations: 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

Pamiparib in mCRPC With HRD or BRCA1/2 Mutation

Phase 2

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Pamiparib

First Posted Date: 2022-04-14

Last Posted Date: 2022-04-14

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT05327621

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Bevacizumab + Nab paclitaxel (intense dose-dense)
Drug: Bevacizumab
Drug: Pamiparib
Drug: Tislelizumab
Drug: Nab paclitaxel

First Posted Date: 2021-09-16

Last Posted Date: 2022-10-20

Lead Sponsor: Tongji Hospital

Target Recruit Count: 160

Registration Number: NCT05044871

Locations: 🇨🇳
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy